Julia Baran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Julia Baran has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Karolina Wojciechowska
Śniadeckiego Voivodeship Hospital in Bialystok, ul. M. C. Skłodowskiej 26, 15-278 Białystok, Poland
11 shared publications - Wiktor Warych
Śniadeckiego Voivodeship Hospital in Bialystok, ul. M. C. Skłodowskiej 26, 15-278 Białystok, Poland
11 shared publications - Julia Martowska
Śniadeckiego Voivodeship Hospital in Bialystok, ul. M. C. Skłodowskiej 26, 15-278 Białystok, Poland
9 shared publications - Ewelina Choroszewska
Śniadeckiego Voivodeship Hospital in Bialystok
8 shared publications - Patrycja Zabrocka
Medical University of Bialystok
8 shared publications - Agnieszka Bullmann
Szpital Specjalistyczny im. F. Ceynowy, ul. dr. Alojzego Jagalskiego 10, 84-200 Wejherowo, Poland
5 shared publications
Latest Publications
- Open Access
- 5 April 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 53, 70252
Depression and Anxiety as Aspects of Mental Health in Celiac Disease: A Systematic Review and Meta-Analytical Synthesis
Background:Celiac disease (CD) is a chronic immune-mediated disorder with significant extraintestinal manifestations, including neuropsychiatric symptoms. Depression and anxiety are among the most frequently reported and may substantially affect quality of life. Aim:This review aimed to evaluate the prevalence of depressive and anxiety symptoms in adults and children with CD and to assess the influence of adherence to a GFD on psychiatric outcomes. Material and Methods:A structured narrative review with meta-analytical synthesis was conducted using studies identified through PubMed/MEDLINE, Scopus, and Web of Science. Observational studies, clinical cohorts, and existing meta-analyses were included. Findings were integrated narratively, considering age, disease status, and dietary adherence. Results:Depressive symptoms were consistently more prevalent in individuals with CD, particularly in untreated or newly diagnosed patients. Partial improvement was observed following initiation of a gluten-free diet although symptoms often persisted. Findings regarding anxiety were heterogeneous. Psychiatric outcomes were influenced by disease activity, age, nutritional status, and psychosocial factors. Conclusions:Depression and anxiety are clinically relevant but often underrecognized components of CD. A GFD may alleviate psychological distress but does not fully eliminate psychiatric morbidity, supporting the need for routine mental health screening and multidisciplinary care.
- 5 April 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 53, 70252
Open AccessDepression and Anxiety as Aspects of Mental Health in Celiac Disease: A Systematic Review and Meta-Analytical Synthesis
Background:Celiac disease (CD) is a chronic immune-mediated disorder with significant extraintestinal manifestations, including neuropsychiatric symptoms. Depression and anxiety are among the most frequently reported and may substantially affect quality of life. Aim:This review aimed to evaluate the prevalence of depressive and anxiety symptoms in adults and children with CD and to assess the influence of adherence to a GFD on psychiatric outcomes. Material and Methods:A structured narrative review with meta-analytical synthesis was conducted using studies identified through PubMed/MEDLINE, Scopus, and Web of Science. Observational studies, clinical cohorts, and existing meta-analyses were included. Findings were integrated narratively, considering age, disease status, and dietary adherence. Results:Depressive symptoms were consistently more prevalent in individuals with CD, particularly in untreated or newly diagnosed patients. Partial improvement was observed following initiation of a gluten-free diet although symptoms often persisted. Findings regarding anxiety were heterogeneous. Psychiatric outcomes were influenced by disease activity, age, nutritional status, and psychosocial factors. Conclusions:Depression and anxiety are clinically relevant but often underrecognized components of CD. A GFD may alleviate psychological distress but does not fully eliminate psychiatric morbidity, supporting the need for routine mental health screening and multidisciplinary care.
- Open Access
- 17 February 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 51
Evening Primrose Oil (Oenothera biennis L.) in Women’s Health: A Narrative Review of Clinical Evidence
Evening primrose oil (EPO), derived from the seeds of Oenothera biennis L., has been widely used as a complementary therapeutic agent in various female health conditions. Its biological activity is primarily attributed to its high content of essential omega-6 fatty acids, particularly linoleic acid and γ-linolenic acid, which serve as precursors of anti-inflammatory prostaglandins. Over recent decades, increasing clinical interest has focused on the potential role of EPO in the management of premenstrual syndrome, mastalgia, menopausal symptoms, polycystic ovary syndrome, and other inflammatory or hormone-related disorders affecting women. The present narrative review aims to summarize current evidence regarding the phytochemical composition, proposed mechanisms of action, clinical efficacy, and safety profile of evening primrose oil in women’s health. A comprehensive literature search of electronic databases was conducted, including randomized controlled trials, systematic reviews, meta-analyses, and observational studies. Available evidence suggests that evening primrose oil may provide symptomatic relief in selected conditions, particularly mastalgia and certain menopausal symptoms, while results in premenstrual syndrome and other indications remain inconsistent. Overall, EPO appears to be well tolerated, although its therapeutic effectiveness varies depending on dosage, duration of use, and clinical indication. Further large-scale, well-designed clinical trials are required to establish clear recommendations for its use in general medical practice.
- 17 February 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 51
Open AccessEvening Primrose Oil (Oenothera biennis L.) in Women’s Health: A Narrative Review of Clinical Evidence
Evening primrose oil (EPO), derived from the seeds of Oenothera biennis L., has been widely used as a complementary therapeutic agent in various female health conditions. Its biological activity is primarily attributed to its high content of essential omega-6 fatty acids, particularly linoleic acid and γ-linolenic acid, which serve as precursors of anti-inflammatory prostaglandins. Over recent decades, increasing clinical interest has focused on the potential role of EPO in the management of premenstrual syndrome, mastalgia, menopausal symptoms, polycystic ovary syndrome, and other inflammatory or hormone-related disorders affecting women. The present narrative review aims to summarize current evidence regarding the phytochemical composition, proposed mechanisms of action, clinical efficacy, and safety profile of evening primrose oil in women’s health. A comprehensive literature search of electronic databases was conducted, including randomized controlled trials, systematic reviews, meta-analyses, and observational studies. Available evidence suggests that evening primrose oil may provide symptomatic relief in selected conditions, particularly mastalgia and certain menopausal symptoms, while results in premenstrual syndrome and other indications remain inconsistent. Overall, EPO appears to be well tolerated, although its therapeutic effectiveness varies depending on dosage, duration of use, and clinical indication. Further large-scale, well-designed clinical trials are required to establish clear recommendations for its use in general medical practice.
- Open Access
- 14 February 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 51
The role of ginger (Zingiber officinale) in the management of nausea and vomiting
Nausea and vomiting are common and clinically relevant symptoms associated with a wide range of medical conditions, including chemotherapy and radiotherapy, surgical procedures, pregnancy, and gastrointestinal disorders. Their pathophysiology involves complex interactions between central and peripheral nervous system pathways, neurotransmitters, inflammatory mediators, and gastrointestinal motility. Ginger (Zingiber officinale), a medicinal plant traditionally used to alleviate gastrointestinal discomfort, contains bioactive compounds such as gingerols and shogaols that exhibit anti-inflammatory, prokinetic, and neuro-modulatory properties. This article provides a narrative review of current clinical and experimental evidence regarding the role of ginger in the management of nausea and vomiting, with particular emphasis on chemotherapy-induced nausea and vomiting, postoperative nausea, nausea of pregnancy, and selected gastrointestinal conditions.
- 14 February 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 51
Open AccessThe role of ginger (Zingiber officinale) in the management of nausea and vomiting
Nausea and vomiting are common and clinically relevant symptoms associated with a wide range of medical conditions, including chemotherapy and radiotherapy, surgical procedures, pregnancy, and gastrointestinal disorders. Their pathophysiology involves complex interactions between central and peripheral nervous system pathways, neurotransmitters, inflammatory mediators, and gastrointestinal motility. Ginger (Zingiber officinale), a medicinal plant traditionally used to alleviate gastrointestinal discomfort, contains bioactive compounds such as gingerols and shogaols that exhibit anti-inflammatory, prokinetic, and neuro-modulatory properties. This article provides a narrative review of current clinical and experimental evidence regarding the role of ginger in the management of nausea and vomiting, with particular emphasis on chemotherapy-induced nausea and vomiting, postoperative nausea, nausea of pregnancy, and selected gastrointestinal conditions.
- Open Access
- 4 February 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 51, 68504
The Role of Myo-Inositol in the Management of Metabolic and Reproductive Sequelae of Polycystic Ovary Syndrome: A Comprehensive Review of the Current State of Knowledge
Polycystic Ovary Syndrome (PCOS) represents a heterogeneous and multifaceted endocrinopathy, characterized by extensive metabolic implications, affecting a substantial global cohort of reproductive-age women. Central to its pathogenesis is insulin resistance (IR) and compensatory hyperinsulinemia, which drive both metabolic dysfunction and reproductive failures. Myo-inositol (MI), acting as a vital second messenger for both insulin and follicle-stimulating hormone (FSH), has emerged as a cornerstone therapeutic agent. This comprehensive review evaluates the clinical efficacy of MI, particularly when administered in the physiological 40:1 ratio with D-chiro-inositol (DCI). We analyze its impact on glycemic profiles, hormonal stabilization, and the enhancement of oocyte competence. Based on the 2023 International Evidence-based Guidelines and recent clinical trials, MI represents a safe, well-tolerated, and effective alternative to traditional pharmacological interventions, providing a holistic approach to PCOS management.
- 4 February 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 51, 68504
Open AccessThe Role of Myo-Inositol in the Management of Metabolic and Reproductive Sequelae of Polycystic Ovary Syndrome: A Comprehensive Review of the Current State of Knowledge
Polycystic Ovary Syndrome (PCOS) represents a heterogeneous and multifaceted endocrinopathy, characterized by extensive metabolic implications, affecting a substantial global cohort of reproductive-age women. Central to its pathogenesis is insulin resistance (IR) and compensatory hyperinsulinemia, which drive both metabolic dysfunction and reproductive failures. Myo-inositol (MI), acting as a vital second messenger for both insulin and follicle-stimulating hormone (FSH), has emerged as a cornerstone therapeutic agent. This comprehensive review evaluates the clinical efficacy of MI, particularly when administered in the physiological 40:1 ratio with D-chiro-inositol (DCI). We analyze its impact on glycemic profiles, hormonal stabilization, and the enhancement of oocyte competence. Based on the 2023 International Evidence-based Guidelines and recent clinical trials, MI represents a safe, well-tolerated, and effective alternative to traditional pharmacological interventions, providing a holistic approach to PCOS management.
- Open Access
- 27 January 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 50
The Role Physical Activity in the Prevention and Control of Diabetes Mellitus – A Narrative Review
Diabetes mellitus is one of the most prevalent chronic non-communicable diseases worldwide and constitutes a major public health challenge due to its growing incidence, high morbidity and mortality, and substantial socioeconomic burden. Insufficient physical activity has been identified as a key modifiable risk factor contributing to the development and progression of diabetes, particularly type 2 diabetes mellitus, but also influencing metabolic control and complication risk in type 1 diabetes mellitus. The present narrative review summarizes current evidence regarding the role of physical activity in the prevention and control of diabetes mellitus. A comprehensive analysis of peer-reviewed original studies, systematic reviews, and clinical guidelines was conducted. The available evidence demonstrates that regular physical activity significantly reduces the risk of developing type 2 diabetes, improves glycemic control and insulin sensitivity in individuals with established diabetes, and exerts beneficial effects on cardiovascular fitness, body composition, inflammatory status, and oxidative stress. Furthermore, physical activity has been shown to attenuate the progression of both microvascular and macrovascular complications. These findings support the inclusion of structured physical activity as a fundamental component of diabetes prevention strategies and routine clinical management. Background:Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia resulting from impaired insulin secretion, impaired insulin action, or a combination of both. The global prevalence of diabetes has increased markedly over recent decades, driven by population aging, urbanization, obesity, sedentary lifestyles, and unfavorable dietary patterns. Type 2 diabetes mellitus accounts for more than 90% of all cases and is strongly associated with modifiable lifestyle factors, whereas type 1 diabetes mellitus is primarily autoimmune in origin but similarly associated with elevated cardiovascular risk and reduced life expectancy. Physical inactivity has emerged as an independent risk factor for insulin resistance, impaired glucose tolerance, cardiovascular disease, and premature mortality. Skeletal muscle, the primary site of insulin-mediated glucose uptake, plays a central role in glucose homeostasis and represents a key target for exercise-induced metabolic adaptations. Regular physical activity improves glucose uptake through both insulin-dependent and insulin-independent mechanisms and induces favorable changes in mitochondrial function, lipid metabolism, inflammatory signaling, and antioxidant defense systems. Consequently, increasing attention has been directed toward physical activity as a cost-effective and scalable intervention for diabetes prevention and long-term disease control. Aim:The aim of this review was to evaluate the role of physical activity in the prevention of diabetes mellitus and in the metabolic control and complication management of individuals with established type 1 and type 2 diabetes mellitus. Material and Methods:This narrative review was based on an analysis of peer-reviewed scientific literature, including original research articles, randomized controlled trials, observational studies, systematic reviews, and expert consensus statements. The included publications focused on epidemiology, pathophysiological mechanisms, clinical outcomes, and exercise prescription related to physical activity in diabetes prevention and management. Results:The reviewed evidence consistently demonstrates that regular physical activity is associated with a substantial reduction in the risk of developing type 2 diabetes mellitus. In individuals with established diabetes, physical activity improves glycemic control, insulin sensitivity, lipid profile, blood pressure, and cardiorespiratory fitness. Both aerobic and resistance exercise modalities provide metabolic benefits, with combined training programs yielding the most pronounced effects. Additionally, regular physical activity reduces markers of systemic inflammation and oxidative stress and attenuates the progression of diabetes-related microvascular and macrovascular complications. Conclusions:Physical activity represents a fundamental, evidence-based component of diabetes prevention and management. Its regular incorporation into lifestyle interventions and clinical care is essential for improving metabolic control, reducing complication risk, and enhancing long-term health outcomes in individuals at risk of or living with diabetes mellitus.
- 27 January 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 50
Open AccessThe Role Physical Activity in the Prevention and Control of Diabetes Mellitus – A Narrative Review
Diabetes mellitus is one of the most prevalent chronic non-communicable diseases worldwide and constitutes a major public health challenge due to its growing incidence, high morbidity and mortality, and substantial socioeconomic burden. Insufficient physical activity has been identified as a key modifiable risk factor contributing to the development and progression of diabetes, particularly type 2 diabetes mellitus, but also influencing metabolic control and complication risk in type 1 diabetes mellitus. The present narrative review summarizes current evidence regarding the role of physical activity in the prevention and control of diabetes mellitus. A comprehensive analysis of peer-reviewed original studies, systematic reviews, and clinical guidelines was conducted. The available evidence demonstrates that regular physical activity significantly reduces the risk of developing type 2 diabetes, improves glycemic control and insulin sensitivity in individuals with established diabetes, and exerts beneficial effects on cardiovascular fitness, body composition, inflammatory status, and oxidative stress. Furthermore, physical activity has been shown to attenuate the progression of both microvascular and macrovascular complications. These findings support the inclusion of structured physical activity as a fundamental component of diabetes prevention strategies and routine clinical management. Background:Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia resulting from impaired insulin secretion, impaired insulin action, or a combination of both. The global prevalence of diabetes has increased markedly over recent decades, driven by population aging, urbanization, obesity, sedentary lifestyles, and unfavorable dietary patterns. Type 2 diabetes mellitus accounts for more than 90% of all cases and is strongly associated with modifiable lifestyle factors, whereas type 1 diabetes mellitus is primarily autoimmune in origin but similarly associated with elevated cardiovascular risk and reduced life expectancy. Physical inactivity has emerged as an independent risk factor for insulin resistance, impaired glucose tolerance, cardiovascular disease, and premature mortality. Skeletal muscle, the primary site of insulin-mediated glucose uptake, plays a central role in glucose homeostasis and represents a key target for exercise-induced metabolic adaptations. Regular physical activity improves glucose uptake through both insulin-dependent and insulin-independent mechanisms and induces favorable changes in mitochondrial function, lipid metabolism, inflammatory signaling, and antioxidant defense systems. Consequently, increasing attention has been directed toward physical activity as a cost-effective and scalable intervention for diabetes prevention and long-term disease control. Aim:The aim of this review was to evaluate the role of physical activity in the prevention of diabetes mellitus and in the metabolic control and complication management of individuals with established type 1 and type 2 diabetes mellitus. Material and Methods:This narrative review was based on an analysis of peer-reviewed scientific literature, including original research articles, randomized controlled trials, observational studies, systematic reviews, and expert consensus statements. The included publications focused on epidemiology, pathophysiological mechanisms, clinical outcomes, and exercise prescription related to physical activity in diabetes prevention and management. Results:The reviewed evidence consistently demonstrates that regular physical activity is associated with a substantial reduction in the risk of developing type 2 diabetes mellitus. In individuals with established diabetes, physical activity improves glycemic control, insulin sensitivity, lipid profile, blood pressure, and cardiorespiratory fitness. Both aerobic and resistance exercise modalities provide metabolic benefits, with combined training programs yielding the most pronounced effects. Additionally, regular physical activity reduces markers of systemic inflammation and oxidative stress and attenuates the progression of diabetes-related microvascular and macrovascular complications. Conclusions:Physical activity represents a fundamental, evidence-based component of diabetes prevention and management. Its regular incorporation into lifestyle interventions and clinical care is essential for improving metabolic control, reducing complication risk, and enhancing long-term health outcomes in individuals at risk of or living with diabetes mellitus.
- Open Access
- 27 January 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 50
The Role of Curcumin in Obesity: Mechanisms and Metabolic Implications
Obesity is a complex, multifactorial chronic disease associated with metabolic, inflammatory, cardiovascular, renal, and gastrointestinal complications. Increasing interest has been directed toward bioactive dietary compounds with potential anti-obesity properties. Curcumin, the principal polyphenolic compound derived from Curcuma longa, has been extensively investigated for its metabolic, anti-inflammatory, antioxidant, and regulatory effects on adipose tissue, liver metabolism, insulin sensitivity, and gut microbiota. This review summarizes and critically analyzes available evidence regarding the role of curcumin in obesity, drawing on in vitro studies, animal models, clinical trials, and mechanistic investigations. The findings indicate that curcumin supplementation is associated with attenuation of weight gain, adipogenesis, inflammation, insulin resistance, lipid accumulation, and obesity-related organ dysfunction through multiple molecular pathways. However, most available evidence originates from preclinical models, while clinical data remain limited and heterogeneous, highlighting the need for cautious interpretation of translational relevance. Further well-designed, large-scale clinical studies are required to clarify curcumin’s therapeutic potential in obesity management.
- 27 January 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 50
Open AccessThe Role of Curcumin in Obesity: Mechanisms and Metabolic Implications
Obesity is a complex, multifactorial chronic disease associated with metabolic, inflammatory, cardiovascular, renal, and gastrointestinal complications. Increasing interest has been directed toward bioactive dietary compounds with potential anti-obesity properties. Curcumin, the principal polyphenolic compound derived from Curcuma longa, has been extensively investigated for its metabolic, anti-inflammatory, antioxidant, and regulatory effects on adipose tissue, liver metabolism, insulin sensitivity, and gut microbiota. This review summarizes and critically analyzes available evidence regarding the role of curcumin in obesity, drawing on in vitro studies, animal models, clinical trials, and mechanistic investigations. The findings indicate that curcumin supplementation is associated with attenuation of weight gain, adipogenesis, inflammation, insulin resistance, lipid accumulation, and obesity-related organ dysfunction through multiple molecular pathways. However, most available evidence originates from preclinical models, while clinical data remain limited and heterogeneous, highlighting the need for cautious interpretation of translational relevance. Further well-designed, large-scale clinical studies are required to clarify curcumin’s therapeutic potential in obesity management.
- Open Access
- 11 January 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 49, 67803
The Role of Gut Microbiota in the Pathophysiology of Depression: A Narrative Review
Depression is a complex psychiatric disorder with incompletely understood pathophysiology. Increasing evidence implicates gut microbiota dysbiosis in depression through the microbiota-gut-brain axis. This narrative review summarizes experimental and clinical studies published between 2013 and 2025 examining associations between gut microbiota and depressive disorders. Findings indicate that depression is linked to altered microbial diversity, immune activation, intestinal barrier dysfunction, dysregulation of the hypothalamic-pituitary-adrenal axis, and disturbances in tryptophan metabolism. While preclinical studies suggest a potential causal role of gut microbiota in depressive-like behavior, human evidence remains largely associative. Modulation of gut microbiota represents a promising but still exploratory direction for future depression research and therapy.
- 11 January 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 49, 67803
Open AccessThe Role of Gut Microbiota in the Pathophysiology of Depression: A Narrative Review
Depression is a complex psychiatric disorder with incompletely understood pathophysiology. Increasing evidence implicates gut microbiota dysbiosis in depression through the microbiota-gut-brain axis. This narrative review summarizes experimental and clinical studies published between 2013 and 2025 examining associations between gut microbiota and depressive disorders. Findings indicate that depression is linked to altered microbial diversity, immune activation, intestinal barrier dysfunction, dysregulation of the hypothalamic-pituitary-adrenal axis, and disturbances in tryptophan metabolism. While preclinical studies suggest a potential causal role of gut microbiota in depressive-like behavior, human evidence remains largely associative. Modulation of gut microbiota represents a promising but still exploratory direction for future depression research and therapy.
- Open Access
- 2 January 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 49
The Role of Omega-3 Fatty Acids in the Pathophysiology and Treatment of Migraine: An Updated Review of Clinical Evidence, Mechanistic Pathways and Nutritional Recommendations
Migraine is a complex neurological disorder in which neuroinflammatory processes, altered neuronal excitability, mitochondrial dysfunction, and changes within the immunological microenvironment play key roles in its pathophysiology. Omega-3 fatty acids, particularly EPA and DHA, exhibit potent anti-inflammatory, pro-resolving, and neuroprotective effects. This article provides a narrative review of the literature describing the mechanisms of action of omega-3 fatty acids and their clinical efficacy in studies related to migraine. Background: Migraine is one of the most diagnosed neurological disorders and significantly impacts patients’ quality of life. Current understanding highlights its neuro-immunological nature, involving complex interactions between neurons, glial cells, and inflammatory mediators. In recent years, increasing attention has been directed toward nutritional factors that may modulate the course of the disorder, including omega-3 fatty acids. Aim: The aim of this article is to provide an expanded narrative review of the mechanisms of action of omega-3 fatty acids and to evaluate their clinical effectiveness in the context of migraine prevention and treatment. Material and Methods: This review has a narrative character. The literature was searched in the PubMed, Scopus, and Web of Science databases for the years 2000- 2025, using keywords related to migraine and omega-3 fatty acids (including migraine, omega-3 fatty acids, EPA, DHA, resolvins, CGRP). Experimental studies, clinical trials, and reviews addressing the role of EPA and DHA in the pathophysiology and treatment of migraine were included. Publications of low methodological quality or lacking complete data were excluded. The aim of this review was to provide a synthetic summary of current knowledge rather than to conduct a systematic review. Results: The reviewed evidence indicates that omega-3 fatty acids, particularly EPA and DHA, influence several biological pathways relevant to migraine pathophysiology. Mechanistic studies consistently demonstrate their ability to modulate pro-inflammatory lipid mediators, enhance the production of pro-resolving molecules, stabilize neuronal membranes, improve mitochondrial efficiency, and reduce CGRP-related neurovascular activation. Clinical trials show heterogeneous but generally favourable outcomes, with the most pronounced benefits observed in interventions that include increased EPA intake combined with dietary reduction of omega-6 fatty acids and treatment durations of at least 12 weeks. Adjunctive therapies involving omega-3 fatty acids, such as combinations with valproate or metabolic cofactors, also suggest potential synergistic effects. Evidence in paediatric populations remains limited and inconsistent. Conclusions: Omega-3 fatty acids represent a promising adjunctive strategy in migraine management, supported by mechanistic plausibility and growing clinical evidence. Their therapeutic potential appears strongly context-dependent, particularly on dietary omega-6 intake and treatment duration. EPA-rich formulations may offer enhanced anti-inflammatory and migraine-preventive effects, while DHA contributes to neuroprotection and neuronal stability. Although current findings are encouraging, larger and methodologically rigorous clinical trials are needed to establish optimal dosing, treatment protocols, and biomarkers that could guide personalized omega-3-based interventions in migraine care.
- 2 January 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 49
Open AccessThe Role of Omega-3 Fatty Acids in the Pathophysiology and Treatment of Migraine: An Updated Review of Clinical Evidence, Mechanistic Pathways and Nutritional Recommendations
Migraine is a complex neurological disorder in which neuroinflammatory processes, altered neuronal excitability, mitochondrial dysfunction, and changes within the immunological microenvironment play key roles in its pathophysiology. Omega-3 fatty acids, particularly EPA and DHA, exhibit potent anti-inflammatory, pro-resolving, and neuroprotective effects. This article provides a narrative review of the literature describing the mechanisms of action of omega-3 fatty acids and their clinical efficacy in studies related to migraine. Background: Migraine is one of the most diagnosed neurological disorders and significantly impacts patients’ quality of life. Current understanding highlights its neuro-immunological nature, involving complex interactions between neurons, glial cells, and inflammatory mediators. In recent years, increasing attention has been directed toward nutritional factors that may modulate the course of the disorder, including omega-3 fatty acids. Aim: The aim of this article is to provide an expanded narrative review of the mechanisms of action of omega-3 fatty acids and to evaluate their clinical effectiveness in the context of migraine prevention and treatment. Material and Methods: This review has a narrative character. The literature was searched in the PubMed, Scopus, and Web of Science databases for the years 2000- 2025, using keywords related to migraine and omega-3 fatty acids (including migraine, omega-3 fatty acids, EPA, DHA, resolvins, CGRP). Experimental studies, clinical trials, and reviews addressing the role of EPA and DHA in the pathophysiology and treatment of migraine were included. Publications of low methodological quality or lacking complete data were excluded. The aim of this review was to provide a synthetic summary of current knowledge rather than to conduct a systematic review. Results: The reviewed evidence indicates that omega-3 fatty acids, particularly EPA and DHA, influence several biological pathways relevant to migraine pathophysiology. Mechanistic studies consistently demonstrate their ability to modulate pro-inflammatory lipid mediators, enhance the production of pro-resolving molecules, stabilize neuronal membranes, improve mitochondrial efficiency, and reduce CGRP-related neurovascular activation. Clinical trials show heterogeneous but generally favourable outcomes, with the most pronounced benefits observed in interventions that include increased EPA intake combined with dietary reduction of omega-6 fatty acids and treatment durations of at least 12 weeks. Adjunctive therapies involving omega-3 fatty acids, such as combinations with valproate or metabolic cofactors, also suggest potential synergistic effects. Evidence in paediatric populations remains limited and inconsistent. Conclusions: Omega-3 fatty acids represent a promising adjunctive strategy in migraine management, supported by mechanistic plausibility and growing clinical evidence. Their therapeutic potential appears strongly context-dependent, particularly on dietary omega-6 intake and treatment duration. EPA-rich formulations may offer enhanced anti-inflammatory and migraine-preventive effects, while DHA contributes to neuroprotection and neuronal stability. Although current findings are encouraging, larger and methodologically rigorous clinical trials are needed to establish optimal dosing, treatment protocols, and biomarkers that could guide personalized omega-3-based interventions in migraine care.
- Open Access
- 2 January 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 49
The Role of Omega-3 Fatty Acids in the Pathophysiology and Treatment of Migraine: An Updated Review of Clinical Evidence, Mechanistic Pathways and Nutritional Recommendations
Migraine is a complex neurological disorder in which neuroinflammatory processes, altered neuronal excitability, mitochondrial dysfunction, and changes within the immunological microenvironment play key roles in its pathophysiology. Omega-3 fatty acids, particularly EPA and DHA, exhibit potent anti-inflammatory, pro-resolving, and neuroprotective effects. This article provides a narrative review of the literature describing the mechanisms of action of omega-3 fatty acids and their clinical efficacy in studies related to migraine. Background: Migraine is one of the most diagnosed neurological disorders and significantly impacts patients’ quality of life. Current understanding highlights its neuro-immunological nature, involving complex interactions between neurons, glial cells, and inflammatory mediators. In recent years, increasing attention has been directed toward nutritional factors that may modulate the course of the disorder, including omega-3 fatty acids. Aim: The aim of this article is to provide an expanded narrative review of the mechanisms of action of omega-3 fatty acids and to evaluate their clinical effectiveness in the context of migraine prevention and treatment. Material and Methods: This review has a narrative character. The literature was searched in the PubMed, Scopus, and Web of Science databases for the years 2000- 2025, using keywords related to migraine and omega-3 fatty acids (including migraine, omega-3 fatty acids, EPA, DHA, resolvins, CGRP). Experimental studies, clinical trials, and reviews addressing the role of EPA and DHA in the pathophysiology and treatment of migraine were included. Publications of low methodological quality or lacking complete data were excluded. The aim of this review was to provide a synthetic summary of current knowledge rather than to conduct a systematic review. Results: The reviewed evidence indicates that omega-3 fatty acids, particularly EPA and DHA, influence several biological pathways relevant to migraine pathophysiology. Mechanistic studies consistently demonstrate their ability to modulate pro-inflammatory lipid mediators, enhance the production of pro-resolving molecules, stabilize neuronal membranes, improve mitochondrial efficiency, and reduce CGRP-related neurovascular activation. Clinical trials show heterogeneous but generally favourable outcomes, with the most pronounced benefits observed in interventions that include increased EPA intake combined with dietary reduction of omega-6 fatty acids and treatment durations of at least 12 weeks. Adjunctive therapies involving omega-3 fatty acids, such as combinations with valproate or metabolic cofactors, also suggest potential synergistic effects. Evidence in paediatric populations remains limited and inconsistent. Conclusions: Omega-3 fatty acids represent a promising adjunctive strategy in migraine management, supported by mechanistic plausibility and growing clinical evidence. Their therapeutic potential appears strongly context-dependent, particularly on dietary omega-6 intake and treatment duration. EPA-rich formulations may offer enhanced anti-inflammatory and migraine-preventive effects, while DHA contributes to neuroprotection and neuronal stability. Although current findings are encouraging, larger and methodologically rigorous clinical trials are needed to establish optimal dosing, treatment protocols, and biomarkers that could guide personalized omega-3-based interventions in migraine care.
- 2 January 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 49
Open AccessThe Role of Omega-3 Fatty Acids in the Pathophysiology and Treatment of Migraine: An Updated Review of Clinical Evidence, Mechanistic Pathways and Nutritional Recommendations
Migraine is a complex neurological disorder in which neuroinflammatory processes, altered neuronal excitability, mitochondrial dysfunction, and changes within the immunological microenvironment play key roles in its pathophysiology. Omega-3 fatty acids, particularly EPA and DHA, exhibit potent anti-inflammatory, pro-resolving, and neuroprotective effects. This article provides a narrative review of the literature describing the mechanisms of action of omega-3 fatty acids and their clinical efficacy in studies related to migraine. Background: Migraine is one of the most diagnosed neurological disorders and significantly impacts patients’ quality of life. Current understanding highlights its neuro-immunological nature, involving complex interactions between neurons, glial cells, and inflammatory mediators. In recent years, increasing attention has been directed toward nutritional factors that may modulate the course of the disorder, including omega-3 fatty acids. Aim: The aim of this article is to provide an expanded narrative review of the mechanisms of action of omega-3 fatty acids and to evaluate their clinical effectiveness in the context of migraine prevention and treatment. Material and Methods: This review has a narrative character. The literature was searched in the PubMed, Scopus, and Web of Science databases for the years 2000- 2025, using keywords related to migraine and omega-3 fatty acids (including migraine, omega-3 fatty acids, EPA, DHA, resolvins, CGRP). Experimental studies, clinical trials, and reviews addressing the role of EPA and DHA in the pathophysiology and treatment of migraine were included. Publications of low methodological quality or lacking complete data were excluded. The aim of this review was to provide a synthetic summary of current knowledge rather than to conduct a systematic review. Results: The reviewed evidence indicates that omega-3 fatty acids, particularly EPA and DHA, influence several biological pathways relevant to migraine pathophysiology. Mechanistic studies consistently demonstrate their ability to modulate pro-inflammatory lipid mediators, enhance the production of pro-resolving molecules, stabilize neuronal membranes, improve mitochondrial efficiency, and reduce CGRP-related neurovascular activation. Clinical trials show heterogeneous but generally favourable outcomes, with the most pronounced benefits observed in interventions that include increased EPA intake combined with dietary reduction of omega-6 fatty acids and treatment durations of at least 12 weeks. Adjunctive therapies involving omega-3 fatty acids, such as combinations with valproate or metabolic cofactors, also suggest potential synergistic effects. Evidence in paediatric populations remains limited and inconsistent. Conclusions: Omega-3 fatty acids represent a promising adjunctive strategy in migraine management, supported by mechanistic plausibility and growing clinical evidence. Their therapeutic potential appears strongly context-dependent, particularly on dietary omega-6 intake and treatment duration. EPA-rich formulations may offer enhanced anti-inflammatory and migraine-preventive effects, while DHA contributes to neuroprotection and neuronal stability. Although current findings are encouraging, larger and methodologically rigorous clinical trials are needed to establish optimal dosing, treatment protocols, and biomarkers that could guide personalized omega-3-based interventions in migraine care.
- Open Access
- 29 November 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 47, 66793
The Role of Physical Activity in Gut–Brain Axis Regulation and Cognitive Enhancement in Schizophrenia
Background: Recent research highlights the growing importance of the gut–brain axis in neuropsychiatric disorders, including schizophrenia. Particular attention is given to microbial dysbiosis and its influence on neurotransmitter dynamics, systemic inflammation, and cognitive function. Schizophrenia is marked by progressive impairments in attention, working memory, and executive function, often accompanied by hippocampal atrophy—deficits not fully addressed by standard pharmacotherapy. Aim: This review aims to elucidate the mechanisms through which gut microbiota influence neurotransmitter synthesis and cognitive regulation in schizophrenia, and to evaluate the role of exercise as a potential modulator of both microbiota composition and neuroplasticity. Material and Methods: A systematic literature review was conducted on March 18, 2025, using a Python-based script to extract relevant studies from PubMed. The search focused on the interactions between schizophrenia, gut microbiota, neurotransmitter systems, and the effects of exercise-based interventions. Results: Evidence from clinical and preclinical studies indicates that alterations in gut microbiota significantly affect the synthesis of neuroactive compounds such as serotonin, GABA, and dopamine. Moreover, structured exercise programs have been shown to improve cognitive function, increase hippocampal volume, and positively modulate gut microbial composition, suggesting synergistic benefits when combined with conventional treatment. Conclusions: Targeted interventions addressing the gut–brain axis—through microbiota modulation and exercise therapy—represent promising adjunctive strategies in the treatment of schizophrenia. These approaches may enhance neurocognitive outcomes and support more personalized, holistic models of care.
- 29 November 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 47, 66793
Open AccessThe Role of Physical Activity in Gut–Brain Axis Regulation and Cognitive Enhancement in Schizophrenia
Background: Recent research highlights the growing importance of the gut–brain axis in neuropsychiatric disorders, including schizophrenia. Particular attention is given to microbial dysbiosis and its influence on neurotransmitter dynamics, systemic inflammation, and cognitive function. Schizophrenia is marked by progressive impairments in attention, working memory, and executive function, often accompanied by hippocampal atrophy—deficits not fully addressed by standard pharmacotherapy. Aim: This review aims to elucidate the mechanisms through which gut microbiota influence neurotransmitter synthesis and cognitive regulation in schizophrenia, and to evaluate the role of exercise as a potential modulator of both microbiota composition and neuroplasticity. Material and Methods: A systematic literature review was conducted on March 18, 2025, using a Python-based script to extract relevant studies from PubMed. The search focused on the interactions between schizophrenia, gut microbiota, neurotransmitter systems, and the effects of exercise-based interventions. Results: Evidence from clinical and preclinical studies indicates that alterations in gut microbiota significantly affect the synthesis of neuroactive compounds such as serotonin, GABA, and dopamine. Moreover, structured exercise programs have been shown to improve cognitive function, increase hippocampal volume, and positively modulate gut microbial composition, suggesting synergistic benefits when combined with conventional treatment. Conclusions: Targeted interventions addressing the gut–brain axis—through microbiota modulation and exercise therapy—represent promising adjunctive strategies in the treatment of schizophrenia. These approaches may enhance neurocognitive outcomes and support more personalized, holistic models of care.